Ibudilast is a potent and selective inhibitor of the cytokine phosphodiesterase-4 (PDE4), with selectivity for the isoforms PDE4A and PDE4B, which are found in monocytes/macrophages and type II alveolar cells. PDE4A and PDE4B are linked with many inflammatory conditions, including multiple sclerosis (MS), and their inhibition is a therapeutic target to decrease inflammation.
Ibudilast has demonstrated efficacy in reducing the rate of whole brain atrophy in primary progressive MS patients and in reducing the rate of progression of disability in relapsing-remitting MS patients. Ibudilast is currently being tested in a Phase II clinical trial for the treatment of ALS.
In addition to its anti-inflammatory properties, ibudilast has demonstrated neuroprotective and neurotherapeutic effects in animal models of Alzheimer's disease (AD), Parkinson's disease (PD), and cerebral ischemia.
|Ibudilast For Sale|
|Molar Mass||230.31 g/mol|